Strides Pharma Science shares will be in focus on September 15 after the USFDA issued a Form 483 with three observations following a routine cGMP inspection of the company's formulations facility at Alathur, Chennai. According to reports from Moneycontrol, the USFDA conducted the inspection from September 2 to 11, 2026. The company has stated it will respond to the observations within the stipulated timeframe.
This marks the second regulatory observation for Strides Pharma in recent months. As reported by Moneycontrol, in August, the company's Bengaluru facility received an Establishment Inspection Report (EIR) from the USFDA after a cGMP inspection conducted from May 12 to 20, which concluded with five observations. The company had responded to those observations within the stipulated timeframe.
In the previous trading session, the share closed at ₹1,186.10, down ₹31.55, or 2.59 percent. According to Moneycontrol, the share touched a 52-week high of ₹1,231.45 and a 52-week low of ₹769.60 on May 12, 2026, and January 29, 2026, respectively. Currently, the stock is trading 3.68 percent below its 52-week high and 54.12 percent above its 52-week low. The company's market capitalisation stands at ₹10,932.61 crore.
Despite regulatory concerns, Strides Pharma has demonstrated strong financial performance. As reported by Moneycontrol, in the quarter ended June 2026, the company posted a 57.3% jump in net profit to ₹156.91 crore from ₹99.61 crore in June 2025. The share price has gained more than 30% in the last six months, indicating positive investor sentiment despite recent regulatory developments.
